Rabbit Recombinant Monoclonal LYPD3 antibody. Suitable for IHC-P, IP, WB and reacts with Human samples. Cited in 4 publications.
IgG
Rabbit
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
IHC-P | IP | WB | |
---|---|---|---|
Human | Tested | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes For unpurified use at 1/100 - 1/250. Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10 - 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Select an associated product type
Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.
C4.4A, UNQ491/PRO1007, UNQ491/PRO1007, C4.4A, LYPD3, Ly6/PLAUR domain-containing protein 3, GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein, MIG-C4
Rabbit Recombinant Monoclonal LYPD3 antibody. Suitable for IHC-P, IP, WB and reacts with Human samples. Cited in 4 publications.
IgG
Rabbit
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EPR9107
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
LYPD3 also known as C4.4A is a glycosylphosphatidylinositol (GPI)-anchored protein with a molecular weight of approximately 40 kDa. It belongs to the Ly6/PLAUR domain family. This protein is mainly expressed in stratified epithelia and also found in some other tissues. LYPD3 shows higher expression levels in certain cancer cell types indicating its role in tumorigenesis.
LYPD3 functions in cellular adhesion and migration processes. It interacts with extracellular matrix components facilitating the movement and positioning of cells. It acts as a part of a protein complex that is important for cell communication and tissue organization. Its high expression in some cancer types suggests its involvement in processes that drive cancer progression including metastasis.
LYPD3 participates in key signaling cascades including integrin-mediated pathways. These pathways are important for mediating cell-matrix interactions and influence cell movement and survival. LYPD3 has known interactions with integrin proteins suggesting a collaborative role that modulates cell adhesion dynamics. These interactions make it an important player in cell migration and invasion processes that are pivotal for normal physiological events and pathological conditions.
LYPD3 shows significant involvement in cancers such as squamous cell carcinoma and prostate cancer. The protein aids the metastatic spread of these cancers by promoting cell migration and invasion. It has been associated with other proteins like laminin which supports cancer cell detachment and dissemination. Understanding LYPD3's role in cancer biology helps in identifying therapeutic targets for impeding cancer progression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer: 5% NFDM/TBST
All lanes: Western blot - Anti-LYPD3 antibody [EPR9107] (ab151709) at 1/1000 dilution
Lane 1: HaCaT (Human skin keratinocyte) whole cell lysate at 20 µg
Lane 2: BxPC-3 (Human pancreas adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 3: Human esophagus tissue lysate at 20 µg
All lanes: Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/5000 dilution
Predicted band size: 36 kDa
ab151709 (purified) at 1:50 dilution (2ug) immunoprecipitating LYPD3 in HaCaT (Human skin keratinocyte) whole cell lysate.
Lane 1 (input): HaCaT (Human skin keratinocyte) whole cell lysate 10ug
Lane 2 (+): ab151709 & HaCaT (Human skin keratinocyte) whole cell lysate
Lane 3 (-): Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab151709 in HaCaT (Human skin keratinocyte) whole cell lysate
For western blotting, VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) was used for detection at 1:1000 dilution.
Blocking and diluting buffer: 5% NFDM/TBST.
All lanes: Immunoprecipitation - Anti-LYPD3 antibody [EPR9107] (ab151709)
Predicted band size: 36 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human skin tissue sections labeling LYPD3 with Purified ab151709 at 1:1000 dilution (1.01 μg/ml). Heat mediated antigen retrieval was performed using Antigen Retrieval Buffer (100X Tris-EDTA Buffer, pH 9.0) ab93684 (Tris/EDTA buffer, pH 9.0). Tissue was counterstained with Hematoxylin. ImmunoHistoProbe one step HRP Polymer (ready to use) secondary antibody was used at 1:0 dilution. PBS instead of the primary antibody was used as the negative control.
All lanes: Western blot - Anti-LYPD3 antibody [EPR9107] (ab151709) at 1/1000 dilution
Lane 1: BxPC3 cell lysate at 10 µg
Lane 2: HACAT cell lysate at 10 µg
All lanes: Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 36 kDa
Immunohistochemical analysis of paraffin-embedded Human skin tissue labeling LYPD3 with unpurified ab151709 at 1/100 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com